News Focus
News Focus
Followers 91
Posts 7513
Boards Moderated 1
Alias Born 09/18/2009

Re: None

Thursday, 07/24/2025 3:36:39 PM

Thursday, July 24, 2025 3:36:39 PM

Post# of 111
Very interesting to see Novavax announce the success of their H5N1 vaccine study.

"Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
July 24, 2025...

Potential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts

GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses by either single or two-dose intranasal (IN) or intramuscular (IM) administration in nonhuman primates. Results were published in Nature Communications."

https://ir.novavax.com/press-releases/2025-07-24-Novavaxs-H5N1-Vaccine-Candidate-Demonstrates-Immunogenicity-in-Preclinical-Study

Did Humanigen do something I hoped they would, reformulate lenz for vaccines for IM instead of IV administration? Brilacidin could be the therapeutic responsible for the successful IN administration.

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today